TY - JOUR
T1 - Cell tracking and the development of cell-based therapies
T2 - A view from the cardiovascular cell therapy research network
AU - Rodriguez-Porcel, Martin
AU - Kronenberg, Marvin W.
AU - Henry, Timothy D
AU - Traverse, Jay H.
AU - Pepine, Carl J.
AU - Ellis, Stephen G.
AU - Willerson, James T.
AU - Moyé, Lemuel A.
AU - Simari, Robert D.
PY - 2012/5
Y1 - 2012/5
N2 - Cell-based therapies are being developed for myocardial infarction (MI) and its consequences (e.g., heart failure) as well as refractory angina and critical limb ischemia. The promising results obtained in preclinical studies led to the translation of this strategy to clinical studies. To date, the initial results have been mixed: some studies showed benefit, whereas in others, no benefit was observed. There is a growing consensus among the scientific community that a better understanding of the fate of transplanted cells (e.g., cell homing and viability over time) will be critical for the long-term success of these strategies and that future studies should include an assessment of cell homing, engraftment, and fate as an integral part of the trial design. In this review, different imaging methods and technologies are discussed within the framework of the physiological answers that the imaging strategies can provide, with a special focus on the inherent regulatory issues.
AB - Cell-based therapies are being developed for myocardial infarction (MI) and its consequences (e.g., heart failure) as well as refractory angina and critical limb ischemia. The promising results obtained in preclinical studies led to the translation of this strategy to clinical studies. To date, the initial results have been mixed: some studies showed benefit, whereas in others, no benefit was observed. There is a growing consensus among the scientific community that a better understanding of the fate of transplanted cells (e.g., cell homing and viability over time) will be critical for the long-term success of these strategies and that future studies should include an assessment of cell homing, engraftment, and fate as an integral part of the trial design. In this review, different imaging methods and technologies are discussed within the framework of the physiological answers that the imaging strategies can provide, with a special focus on the inherent regulatory issues.
KW - computed tomography
KW - magnetic resonance imaging
KW - molecular imaging
KW - myocardial infarction
KW - myocardium
KW - positron emission tomography
KW - progenitor cells
KW - single photon emission computed tomography
KW - stem cells
UR - http://www.scopus.com/inward/record.url?scp=84861121992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861121992&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2011.12.018
DO - 10.1016/j.jcmg.2011.12.018
M3 - Review article
C2 - 22595165
AN - SCOPUS:84861121992
SN - 1936-878X
VL - 5
SP - 559
EP - 565
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 5
ER -